Your browser doesn't support javascript.
loading
Bioelectronic cell-based device provides a strategy for the treatment of the experimental model of multiple sclerosis.
Audouard, Emilie; Michel, Fanny; Pierroz, Vanessa; Kim, Taeuk; Rousselot, Lisa; Gillet-Legrand, Béatrix; Dufayet-Chauffaut, Gaëlle; Buchmann, Peter; Florea, Michael; Khel, Alexander; Altynbekova, Kamilya; Delgaldo, Claudia; Escudero, Encarna; Soler, Alejandra Ben Aissa; Cartier, Nathalie; Piguet, Francoise; Folcher, Marc.
Afiliación
  • Audouard E; NeuroGenCell, Paris Brain Institute - ICM, INSERM, CNRS, AP-HP, Sorbonne Université; Hôpital de la Pitié Salpêtrière, Paris, France.
  • Michel F; Department of Biosystems Science and Engineering, D-BSSE, ETH Zürich, Basel, Switzerland.
  • Pierroz V; Department of Biosystems Science and Engineering, D-BSSE, ETH Zürich, Basel, Switzerland.
  • Kim T; Department of Biosystems Science and Engineering, D-BSSE, ETH Zürich, Basel, Switzerland.
  • Rousselot L; NeuroGenCell, Paris Brain Institute - ICM, INSERM, CNRS, AP-HP, Sorbonne Université; Hôpital de la Pitié Salpêtrière, Paris, France.
  • Gillet-Legrand B; NeuroGenCell, Paris Brain Institute - ICM, INSERM, CNRS, AP-HP, Sorbonne Université; Hôpital de la Pitié Salpêtrière, Paris, France.
  • Dufayet-Chauffaut G; NeuroGenCell, Paris Brain Institute - ICM, INSERM, CNRS, AP-HP, Sorbonne Université; Hôpital de la Pitié Salpêtrière, Paris, France.
  • Buchmann P; Department of Biosystems Science and Engineering, D-BSSE, ETH Zürich, Basel, Switzerland.
  • Florea M; Department of Biosystems Science and Engineering, D-BSSE, ETH Zürich, Basel, Switzerland.
  • Khel A; GeneXplain GmbH, Wolfenbuettel, Germany.
  • Altynbekova K; GeneXplain GmbH, Wolfenbuettel, Germany.
  • Delgaldo C; Eurecat, Centre Tecnològic de Catalunya, Functional Printing and Embedded Devices Unit, Mataró, Spain.
  • Escudero E; Eurecat, Centre Tecnològic de Catalunya, Functional Printing and Embedded Devices Unit, Mataró, Spain.
  • Soler ABA; Eurecat, Centre Tecnològic de Catalunya, Functional Printing and Embedded Devices Unit, Mataró, Spain.
  • Cartier N; NeuroGenCell, Paris Brain Institute - ICM, INSERM, CNRS, AP-HP, Sorbonne Université; Hôpital de la Pitié Salpêtrière, Paris, France.
  • Piguet F; NeuroGenCell, Paris Brain Institute - ICM, INSERM, CNRS, AP-HP, Sorbonne Université; Hôpital de la Pitié Salpêtrière, Paris, France.
  • Folcher M; Department of Biosystems Science and Engineering, D-BSSE, ETH Zürich, Basel, Switzerland; Institute of Molecular and Clinical Ophthalmology, IOB, Basel, Switzerland. Electronic address: Marc.folcher@iob.ch.
J Control Release ; 352: 994-1008, 2022 12.
Article en En | MEDLINE | ID: mdl-36370877
Wireless powered optogenetic cell-based implant provides a strategy to deliver subcutaneously therapeutic proteins. Immortalize Human Mesenchymal Stem Cells (hMSC-TERT) expressing the bacteriophytochrome diguanylate cyclase (DGCL) were validated for optogenetic controlled interferon-ß delivery (Optoferon cells) in a bioelectronic cell-based implant. Optoferon cells transcriptomic profiling was used to elaborate an in-silico model of the recombinant interferon-ß production. Wireless optoelectronic device integration was developed using additive manufacturing and injection molding. Implant cell-based optoelectronic interface manufacturing was established to integrate industrial flexible compact low-resistance screen-printed Near Field Communication (NFC) coil antenna. Optogenetic cell-based implant biocompatibility, and device performances were evaluated in the Experimental Autoimmune Encephalomyelitis (EAE) mouse model of multiple sclerosis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Encefalomielitis Autoinmune Experimental / Esclerosis Múltiple Límite: Animals / Humans Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Encefalomielitis Autoinmune Experimental / Esclerosis Múltiple Límite: Animals / Humans Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Países Bajos